1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Skin cancer

Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475

Awaiting development [GID-TA11586] Expected publication date: TBC

  • Project information
  • Project documents

33790-Relatlimab-Nivolumab-for-Melanoma-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)